1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global DNA Repair Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global DNA Repair Drugs Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Technological Advancements
5.2. Disease Prevalence & Incidence Rate Globally With Key Countries
5.3. Pipeline Analysis
5.4. Regulatory Scenario by Region/Globally
5.5. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global DNA Repair Drugs Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Type, 2017-2031
6.3.1. PARP Inhibitors
6.3.2. Alkylating Agents
6.3.3. Others
6.4. Market Attractiveness Analysis, by Drug Type
7. Global DNA Repair Drugs Market Analysis and Forecast, by Dosage Form
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Dosage Form, 2017-2031
7.3.1. Breast Cancer
7.3.2. Ovarian Cancer
7.3.3. Lung Cancer
7.3.4. Head and Neck Cancer
7.3.5. Others
7.4. Market Attractiveness Analysis, by Dosage Form
8. Global DNA Repair Drugs Market Analysis and Forecast, by Dosage Form
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Dosage Form, 2017-2031
8.3.1. Tablets
8.3.2. Capsules
8.3.3. Injectables
8.4. Market Attractiveness Analysis, by Dosage Form
9. Global DNA Repair Drugs Market Analysis and Forecast, by Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Distribution Channel, 2017-2031
9.3.1. Retail Pharmacies
9.3.2. Hospital Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness Analysis, by Distribution Channel
10. Global DNA Repair Drugs Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017-2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Country/Region
11. North America DNA Repair Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Type, 2017-2031
11.2.1. PARP Inhibitors
11.2.2. Alkylating Agents
11.2.3. Others
11.3. Market Value Forecast, by Dosage Form, 2017-2031
11.3.1. Breast Cancer
11.3.2. Ovarian Cancer
11.3.3. Lung Cancer
11.3.4. Head and Neck Cancer
11.3.5. Others
11.4. Market Value Forecast, by Dosage Form, 2017-2031
11.4.1. Tablets
11.4.2. Capsules
11.4.3. Injectables
11.5. Market Value Forecast, by Distribution Channel, 2017-2031
11.5.1. Retail Pharmacies
11.5.2. Hospital Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Drug Type
11.7.2. By Dosage Form
11.7.3. By Dosage Form
11.7.4. By Distribution Channel
11.7.5. By Country/Sub-region
12. Europe DNA Repair Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Type, 2017-2031
12.2.1. PARP Inhibitors
12.2.2. Alkylating Agents
12.2.3. Others
12.3. Market Value Forecast, by Dosage Form, 2017-2031
12.3.1. Breast Cancer
12.3.2. Ovarian Cancer
12.3.3. Lung Cancer
12.3.4. Head and Neck Cancer
12.3.5. Others
12.4. Market Value Forecast, by Dosage Form, 2017-2031
12.4.1. Tablets
12.4.2. Capsules
12.4.3. Injectables
12.5. Market Value Forecast, by Distribution Channel, 2017-2031
12.5.1. Retail Pharmacies
12.5.2. Hospital Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Drug Type
12.7.2. By Dosage Form
12.7.3. By Dosage Form
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region
13. Asia Pacific DNA Repair Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Type, 2017-2031
13.2.1. PARP Inhibitors
13.2.2. Alkylating Agents
13.2.3. Others
13.3. Market Value Forecast, by Dosage Form, 2017-2031
13.3.1. Breast Cancer
13.3.2. Ovarian Cancer
13.3.3. Lung Cancer
13.3.4. Head and Neck Cancer
13.3.5. Others
13.4. Market Value Forecast, by Dosage Form, 2017-2031
13.4.1. Tablets
13.4.2. Capsules
13.4.3. Injectables
13.5. Market Value Forecast, by Distribution Channel, 2017-2031
13.5.1. Retail Pharmacies
13.5.2. Hospital Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Drug Type
13.7.2. By Dosage Form
13.7.3. By Dosage Form
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region
14. Latin America DNA Repair Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Type, 2017-2031
14.2.1. PARP Inhibitors
14.2.2. Alkylating Agents
14.2.3. Others
14.3. Market Value Forecast, by Dosage Form, 2017-2031
14.3.1. Breast Cancer
14.3.2. Ovarian Cancer
14.3.3. Lung Cancer
14.3.4. Head and Neck Cancer
14.3.5. Others
14.4. Market Value Forecast, by Dosage Form, 2017-2031
14.4.1. Tablets
14.4.2. Capsules
14.4.3. Injectables
14.5. Market Value Forecast, by Distribution Channel, 2017-2031
14.5.1. Retail Pharmacies
14.5.2. Hospital Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Drug Type
14.7.2. By Dosage Form
14.7.3. By Dosage Form
14.7.4. By Distribution Channel
14.7.5. By Country/Sub-region
15. Middle East & Africa DNA Repair Drugs Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Drug Type, 2017-2031
15.2.1. PARP Inhibitors
15.2.2. Alkylating Agents
15.2.3. Others
15.3. Market Value Forecast, by Dosage Form, 2017-2031
15.3.1. Breast Cancer
15.3.2. Ovarian Cancer
15.3.3. Lung Cancer
15.3.4. Head and Neck Cancer
15.3.5. Others
15.4. Market Value Forecast, by Dosage Form, 2017-2031
15.4.1. Tablets
15.4.2. Capsules
15.4.3. Injectables
15.5. Market Value Forecast, by Distribution Channel, 2017-2031
15.5.1. Retail Pharmacies
15.5.2. Hospital Pharmacies
15.5.3. Online Pharmacies
15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Drug Type
15.7.2. By Dosage Form
15.7.3. By Application
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2021)
16.3. Company Profiles
16.3.1. AstraZeneca plc
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Clovis Oncology
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. GlaxoSmithKline plc
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Pfizer Inc.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Merck & Co. Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Novartis AG
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Johnson & Johnson
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Bristol Myers Squibb Company
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Onxeo
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/